Discovery Metabolomics & Lipidomics Services
Get the Resource
Download NowExtensive biomarker insights lie beyond the genome, in dynamic metabolites and lipids that read out health, disease, and drug response over time. That is why Sapient has innovated our discovery metabolomics & lipidomics approaches to enable rapid, broad profiling of these small molecule chemistries at an entirely new speed and scale.
Sapient’s proprietary rapid liquid chromatography-mass spectrometry (rLC-MS) systems enable simultaneous capture of more than 15,000 metabolites and lipids per sample, in a single run, with the throughput to process thousands of samples per day.
Our rapid, high throughput workflows provide a robust discovery framework to map, at population-scale, the broad and dynamic landscape of chemical variation in humans – elucidating novel disease mechanisms and physiological states.
What insights can discovery metabolomics enable?
Metabolites and lipids provide the most direct readout of physiological activity, capturing the dynamic biochemical processes that drive disease and therapeutic response. Comprehensive measurement of the human metabolome is essential to explain phenotypic variability among individuals who share similar genetic backgrounds, clinical diagnoses, or lab values.
With discovery metabolomics & lipidomics data, researchers can:
- Define biologically distinct human subpopulations
- Separate disease presence from disease mechanism
- Map functional metabolic states
- Reveal system-wide effects via circulating chemistry
- Capture exposure, microbial, and drug-related biology simultaneously
What makes Sapient's metabolomics & lipidomics services unique?
Our robust discovery metabolomics & lipidomics approaches provide an efficient and scalable way to map functional metabolic states in humans. Our rapid, high throughput workflows combine measurement breadth and speed to unlock biomarker discovery efforts that were previously impractical due to time, cost, or sensitivity constraints.
To ensure the metabolite and lipid biomarkers we discover are both biologically grounded and clinically actionable, we couple deep metabolomic profiling with stringent metabolite identification. Our in‑house collection of more than 13,000 chemical reference standards – spanning fundamental human pathways, biochemical networks, and disease‑relevant mechanisms – enables confident assignment of true molecular identities rather than unresolved features.
Crucially, Sapient is able to carry discovery through to real‑world relevance. As the only multi‑omics partner with a proprietary molecular–clinical resource, DynamiQ™, which includes nontargeted metabolomics data from more than 67,000 human samples, we can place study‑specific findings into broader human context. This allows candidate biomarkers to be contextualized and independently supported across large, heterogeneous cohorts – building confidence in their specificity and translational significance.
Download the fact sheet to learn how Sapient’s discovery metabolomics & lipidomics approaches deliver dynamic insights to decipher disease biology and drug response, supporting:
- Biomarker Discovery & Validation: identifying previously unrecognized pathways driving disease risk and distinguishing between causal and compensatory metabolic changes.
- Patient Stratification: defining molecularly coherent subgroups and improving signal detection in heterogeneous cohorts and/or underpowered studies.
- Mechanistic Insight & MoA Studies: using DynamiQ to confirm and contextualize disease and clinical links of biomarkers observed in your study.
- Deeper Views of Systems Biology: enabling simultaneous profiling of genetic, non-genetic, and exposure biology to close the gap between environment, host biology, and disease phenotype.